美股异动 | Aktis Oncology(AKTS.US)登陆美股市场 开盘股价涨超49%
Aktis OncologyAktis Oncology(US:AKTS) 智通财经网·2026-01-09 16:22

Core Viewpoint - Aktis Oncology has successfully launched on the US stock market, with its stock price increasing over 49% to $26.88, following an IPO price of $18 [1] Company Overview - Aktis Oncology is a clinical-stage oncology company focused on developing alpha-particle radiopharmaceuticals for common solid tumors [1] - The company's pipeline includes Ac-AKY-1189, targeting Nectin-4 expressing cancers, which is currently undergoing a multi-center Phase 1b clinical trial in the US with approximately 150 patients recruited, and preliminary results expected in Q1 2027 [1] - Another drug in development is Ac-AKY-2519, aimed at B7-H3 expressing tumors, with plans to submit an Investigational New Drug (IND) application in 2026 [1]